Health
FDA approves Simtriyo for treating ADHD in children and adults
Health 
Story intelligence
Coverage Single outlet Single-outlet story
Views New Be the first to read
Brief read Under 1 min brief 28 words
Summary
The U.S. Food and Drug Administration has approved Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children 6 years and older weighing ≥20 kg.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
Part of ADHD coverage 33 tracked stories
More from Health
Continue reading recent Health coverage
- Experimental chemotherapy uses stealth tactic to activate inside cancer cellsContinue reading
- RFK Jr.'s ethics filing reveals book deals worth millions of dollarsContinue reading
- Restoring enzyme involved in cellular cleanup could reduce inflammation and scarring from liver disease MASHContinue reading
- ‘Her mental health deteriorated’: family forced to wait years for autism diagnosisContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow